DLL4 and cancer: Antibodies targeting individual Notch receptors and ligands (i.e., JAG1, DLL4) have been developed, showing anti-tumor efficacy against different types of cancers in preclinical studies, with manageable toxicity profiles [41,43,44,45,46,47,48].